COVID-19
PsoProtect Registry Data Update
PsoProtect, a global registry for clinicians to report outcomes of COVID-19 in individuals with psoriasis, has updated their preliminary data
Wednesday, June 15, 2022
International Psoriasis Council
Menu
Advancing Knowledge. Enhancing Care.
Menu
Category: Research
Industry
Amgen Announces New Otezla (Apremilast) Data
Amgen presents new data on the efficacy of apremilast in patients with mild to moderate plaque psoriasis and in patients
Tuesday, April 5, 2022
Industry
Janssen Initiates First-of-its-kind Clinical Study to Bridge Critical Gaps in Care for People of Color With Moderate to Severe Plaque Psoriasis
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the initiation of VISIBLE. VISIBLE is a first-of-its-kind, large-scale prospective clinical
Monday, April 4, 2022
Commentaries
Commentary: Coronavirus disease 2019 (COVID‐19)‐associated hospitalization and mortality in patients with psoriasis: A population‐based study
The safety of treatment for immune-mediated diseases like psoriasis during the COVID-19 pandemic is a matter of concern. In an
Wednesday, July 7, 2021
Research
In the Lab with IPC Councilor Nicole Ward
Dr. Ward is a Professor of Dermatology and Neurosciences at Case Western Reserve University and University Hospitals Case Medical Center
Wednesday, February 3, 2021
Research
2020 Virtual Think Tank Meeting Report
Held virtually on December 11 due to the Coronavirus Pandemic, the 2020 IPC Think Tank convened more than 100 specialists
Monday, January 18, 2021
COVID-19
How to build a registry in record time: an interview with Catherine Smith and Satveer Mahil
The registries, PsoProtect and PsoProtectMe, aim to help health care workers understand how the novel virus affects patients with psoriasis.
Wednesday, September 2, 2020